Medpace Holdings, Inc. $MEDP Shares Bought by Global Retirement Partners LLC

Global Retirement Partners LLC raised its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 366.6% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,773 shares of the company’s stock after buying an additional 1,393 shares during the quarter. Global Retirement Partners LLC’s holdings in Medpace were worth $996,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Optiver Holding B.V. acquired a new position in Medpace in the 3rd quarter valued at $27,000. Steigerwald Gordon & Koch Inc. acquired a new position in Medpace in the 4th quarter valued at $30,000. Elyxium Wealth LLC acquired a new position in Medpace in the 4th quarter valued at $30,000. Quarry LP acquired a new position in Medpace in the 3rd quarter valued at $35,000. Finally, Root Financial Partners LLC acquired a new position in Medpace in the 3rd quarter valued at $38,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Medpace

In related news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the sale, the president directly owned 15,000 shares in the company, valued at $6,829,500. The trade was a 67.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 20.50% of the stock is currently owned by company insiders.

Medpace Price Performance

NASDAQ:MEDP opened at $432.80 on Tuesday. Medpace Holdings, Inc. has a fifty-two week low of $287.17 and a fifty-two week high of $628.92. The stock has a market cap of $12.36 billion, a PE ratio of 27.20, a price-to-earnings-growth ratio of 2.20 and a beta of 1.19. The firm’s fifty day simple moving average is $458.70 and its 200-day simple moving average is $517.79.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. During the same period in the prior year, the company posted $3.67 EPS. The business’s revenue for the quarter was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on MEDP. BMO Capital Markets dropped their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research note on Friday, April 24th. Royal Bank Of Canada dropped their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective on the stock in a research note on Friday, February 13th. Barclays dropped their price objective on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. Finally, Truist Financial lowered their price target on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research note on Wednesday, February 11th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Medpace has a consensus rating of “Hold” and an average price target of $467.08.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.